IMVT - Immunovant

-

$undefined

N/A

(N/A)

Immunovant NASDAQ:IMVT Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Location: | Website: immunovant.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.79B

Cash

560M

Avg Qtr Burn

-60.76M

Short % of Float

18.73%

Insider Ownership

55.82%

Institutional Own.

51.63%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Batoclimab (IMVT-1401) Details
Myasthenia gravis

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 3

Initiation

Batoclimab (IMVT-1401) Details
Chronic inflammatory disorder

Phase 2b

Data readout

IMVT-1402 Details
Autoimmune disease, Warm autoimmune hemolytic anemia

Phase 1

Update

Batoclimab (IMVT-1401) Details
Warm autoimmune hemolytic anemia

Failed

Discontinued